Table 1

Baseline characteristics of study population

CharacteristicsEntire cohort (n=267)
 Age (mean in years (SD))41 (16)
 Female (n (%))156 (58.4)
 Body mass index (mean in kg (SD))80 (21)
 Time on infliximab (median in months (IQR))14 (8–34)
 Combination therapy with an immunomodulator (n (%))144 (53.9)
 On methotrexate (n (%))36 (21.6)
 On a thiopurine (n (%))108 (40.4)
IBD subtype
 CD190 (71.2)
 UC77 (28.8)
CD phenotype
 Luminal/inflammatory (n (%))49 (18.4)
 Structuring (n (%))125 (65.3)
 Penetrating (n (%))90 (47.4)
 Perianal disease (n (%))64 (33.7)
CD location
 Ileal only (n (%))20 (10.5)
 Colonic only (n (%))39 (20.5)
 Ileocolonic (n (%))127 (66.8)
UC location
 Ulcerative proctitis (n (%))2 (2.6)
 Left-sided colitis (n (%))19 (24.7)
 Pancolitis (n (%))56 (72.7)
  • CD, Crohn’s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.